Suppr超能文献

设计、合成、初步的体外和体内评价 N-(2-二乙氨基乙基)-4-[18F]氟苯甲酰胺([18F]-DAFBA):一种新型潜在的 PET 探针,用于成像黑色素瘤肿瘤。

Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors.

机构信息

PET Center, Department of Radiological Sciences, Wake Forest University Medical Center, Winston Salem, NC 27157, USA.

出版信息

Bioconjug Chem. 2009 Mar 18;20(3):583-90. doi: 10.1021/bc8005094.

Abstract

In order to develop a PET radiopharmaceutical to image malignant melanoma, we synthesized N-(2-diethylaminoethyl)-4-[(18)F]fluorobenzamide ([(18)F]-DAFBA). In vitro studies show a high uptake of [(18)F]-DAFBA by the B16F1 melanoma cells. No significant binding was seen for DAFBA to the sigma-1 and sigma-2 receptors in vitro. The in vivo biodistribution studies performed in normal ICR mice showed a low uptake in the normal tissues followed by further elimination of radioactivity from these tissues with time. The biodistribution studies performed in C57 mice bearing the melanoma tumor xenograft showed a rapid uptake of radioactivity in the tumor that reached a plateau within 30 min postinjection. The F-18 uptake in the tumor was 7.00 +/- 2.76, 6.57 +/- 1.66, and 5.80 +/- 0.98%ID/g at 60, 120, and 180 min, respectively. A steady uptake of radioactivity in the tumor and low uptake in normal tissues resulted in high tumor to normal tissue ratios. For example, at 180 min postinjection, the tumor to tissue ratios were 14.90 +/- 6.47, 21.90 +/- 4.68, 32.91 +/- 6.11, 39.73 +/- 11.78, and 6.33 +/- 1.9, for the spleen, lungs, muscle, blood, and liver, respectively. The radioactivity rapidly cleared from the blood pool, and it decreased from 0.68 +/- 0.21%ID/g at 60 min to 0.13 +/- 0.03%ID/g at 180 min. The F-18 uptake in the bones at 60, 120, and 180 min was 0.91 +/- 0.27, 0.57 +/- 0.32, and 0.17 +/- 0.05%ID/g, respectively. This low uptake in the bones reflects its in vivo resistance toward defluorination. A low residual activity in normal tissues and a high tumor uptake signifies the superior imaging potential of this compound. Because of these positive traits, [(18)F]-DAFBA could help delineate the tumor and its metastases when used for imaging applications. Further in vivo studies are underway to assess the potential of [(18)F]-DAFBA as a promising PET imaging probe.

摘要

为了开发一种用于成像恶性黑色素瘤的 PET 放射性药物,我们合成了 N-(2-二乙基氨基乙基)-4-[(18)F]氟苯甲酰胺([(18)F]-DAFBA)。体外研究表明,B16F1 黑色素瘤细胞对[(18)F]-DAFBA 有很高的摄取率。在体外,DAFBA 与 sigma-1 和 sigma-2 受体没有明显的结合。在正常 ICR 小鼠中进行的体内生物分布研究表明,正常组织的摄取率较低,随后随着时间的推移,这些组织中的放射性活性进一步消除。在携带黑色素瘤肿瘤异种移植物的 C57 小鼠中进行的生物分布研究表明,放射性物质在肿瘤中的摄取速度很快,在注射后 30 分钟内达到平台期。肿瘤中的 F-18 摄取率分别为 60、120 和 180 分钟时的 7.00 +/- 2.76、6.57 +/- 1.66 和 5.80 +/- 0.98%ID/g。肿瘤中放射性物质的稳定摄取和正常组织中的低摄取导致了高肿瘤与正常组织的比值。例如,在注射后 180 分钟时,肿瘤与组织的比值分别为 14.90 +/- 6.47、21.90 +/- 4.68、32.91 +/- 6.11、39.73 +/- 11.78 和 6.33 +/- 1.9,分别为脾脏、肺、肌肉、血液和肝脏。放射性物质从血池迅速清除,从 60 分钟时的 0.68 +/- 0.21%ID/g 降至 180 分钟时的 0.13 +/- 0.03%ID/g。60、120 和 180 分钟时骨骼中的 F-18 摄取率分别为 0.91 +/- 0.27、0.57 +/- 0.32 和 0.17 +/- 0.05%ID/g。骨骼中的这种低摄取反映了其体内对脱氟的抵抗力。正常组织中的残留活性低,肿瘤摄取率高,表明该化合物具有优异的成像潜力。由于这些积极的特征,[(18)F]-DAFBA 可用于成像应用时有助于描绘肿瘤及其转移灶。正在进行进一步的体内研究,以评估 [(18)F]-DAFBA 作为一种有前途的 PET 成像探针的潜力。

相似文献

2
4-C-Methoxy -(2-Diethylaminoethyl) Benzamide: A Novel Probe to Selectively Target Melanoma.
J Nucl Med. 2017 May;58(5):827-832. doi: 10.2967/jnumed.116.184564. Epub 2016 Dec 15.
3
Melanin-targeted preclinical PET imaging of melanoma metastasis.
J Nucl Med. 2009 Oct;50(10):1692-9. doi: 10.2967/jnumed.109.066175. Epub 2009 Sep 16.
5
Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Nucl Med Biol. 2011 May;38(4):461-75. doi: 10.1016/j.nucmedbio.2010.11.004. Epub 2011 Feb 4.
6
[F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4.
Nucl Med Biol. 2018 May;60:37-44. doi: 10.1016/j.nucmedbio.2018.01.004. Epub 2018 Jan 31.
7
Ultrasensitive detection of malignant melanoma using PET molecular imaging probes.
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12991-12999. doi: 10.1073/pnas.1922313117. Epub 2020 May 21.
8
-(2-(Dimethylamino)Ethyl)-4-F-Fluorobenzamide: A Novel Molecular Probe for High-Contrast PET Imaging of Malignant Melanoma.
J Nucl Med. 2019 Jul;60(7):924-929. doi: 10.2967/jnumed.118.221416. Epub 2018 Dec 14.
10
F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of neuroendocrine tumors (NETs).
Eur J Pharm Sci. 2024 Feb 1;193:106671. doi: 10.1016/j.ejps.2023.106671. Epub 2023 Dec 16.

引用本文的文献

2
First-in-human PET imaging and evaluation of melanin-targeted [F]DMPY2 in malignant melanoma patients.
Theranostics. 2025 May 7;15(13):6100-6110. doi: 10.7150/thno.109243. eCollection 2025.
3
More than Just Skin-Deep: A Review of Imaging's Role in Guiding CAR T-Cell Therapy for Advanced Melanoma.
Diagnostics (Basel). 2023 Mar 5;13(5):992. doi: 10.3390/diagnostics13050992.
5
MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.
Acta Pharmacol Sin. 2022 Dec;43(12):3034-3044. doi: 10.1038/s41401-022-00970-y. Epub 2022 Aug 25.
6
Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.
Diagnostics (Basel). 2022 Apr 29;12(5):1116. doi: 10.3390/diagnostics12051116.
8
Ultrasensitive detection of malignant melanoma using PET molecular imaging probes.
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12991-12999. doi: 10.1073/pnas.1922313117. Epub 2020 May 21.
9
-(2-(Dimethylamino)Ethyl)-4-F-Fluorobenzamide: A Novel Molecular Probe for High-Contrast PET Imaging of Malignant Melanoma.
J Nucl Med. 2019 Jul;60(7):924-929. doi: 10.2967/jnumed.118.221416. Epub 2018 Dec 14.
10
PET and SPECT imaging of melanoma: the state of the art.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):132-150. doi: 10.1007/s00259-017-3839-5. Epub 2017 Oct 30.

本文引用的文献

1
Peptide-targeted radionuclide therapy for melanoma.
Crit Rev Oncol Hematol. 2008 Sep;67(3):213-28. doi: 10.1016/j.critrevonc.2008.02.006. Epub 2008 Apr 2.
2
Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma.
J Med Chem. 2007 Jul 26;50(15):3561-72. doi: 10.1021/jm0701627. Epub 2007 Jun 28.
4
Iodide benzamides for the in-vivo detection of melanoma and metastases.
Melanoma Res. 2006 Feb;16(1):37-43. doi: 10.1097/01.cmr.0000195701.73192.7b.
8
A role for FDG-PET in the surgical management of stage IV melanoma.
Ann Surg Oncol. 2004 Aug;11(8):721-2. doi: 10.1245/ASO.2004.06.923. Epub 2004 Jul 12.
9
Baseline staging in cutaneous malignant melanoma.
Br J Dermatol. 2004 Apr;150(4):677-86. doi: 10.1111/j.0007-0963.2004.05870.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验